SV

Street Verdict

Analyst Scorecard

PARKHOSPS · NSE

Park Medi World Limited

₹238.05

+0.41% (+₹0.97)

Prev. close

₹237.08

Volume

2,62,559

Delivery %

48.7%

As of

20 Nov 2026

Price history

₹238.05-₹38.8 (-14.01%) · 3M
18 Aug 2026 → 20 Nov 2026
22024026028018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

1 · 1 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Park Medi World Limited

Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone marrow transplant, iMARS / robot-assisted surgery. It also offers bariatric surgery, anaesthesiology, critical care, chest and respiratory diseases, dental care, dermatology, endocrinology, paediatrics, internal medicine and geriatrics, rheumatology, ENT, ophthalmology, obstetrics and gynaecology, interventional radiology and imaging, psychiatry, pathology and microbiology, paediatric surgery, fertility management, nuclear medicine services. It operates NABH accredited multi-super specialty hospitals under the Park brand name. Park Medi World Limited was founded in 2005 and is headquartered in Gurugram, India.

Details

Sector

Healthcare

Industry

Medical Care Facilities

CEO

Dr. Sanjay Sharma

Headquarters

Gurugram

Employees

6,423

Key stats

Market cap

₹9,953.85 Cr

P/E ratio (TTM)

35.1

Dividend yield

0.00%

EPS (TTM)

₹6.57

Beta (1Y · daily vs NIFTY 50)

0.80

Shares float

6.71 Cr

EPS · quarter ended Jun 2026

₹2.05

Financial Performance

01 · Financials

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹0%5%10%15%20%FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

02.557.5₹FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-50%0%50%100%FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr₹0×0.25×0.5×0.75×1×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr₹FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

0 Cr250 Cr500 Cr750 Cr₹FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY23FY24FY25FY26
₹1,252.38 Cr₹1,229.06 Cr₹1,391.79 Cr₹1,679.36 Cr
EBITDA
₹404.74 Cr₹338.27 Cr₹402.15 Cr₹475.93 Cr
₹219.67 Cr₹153.49 Cr₹201.64 Cr₹258.12 Cr
Diluted EPS
₹5.09₹3.55₹4.67₹6.87

Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Net income for Mar 2026 could not be checked against the company's own annual report: this page shows ₹258.12 Cr while the annual report gives ₹36.62 Cr (85.8% apart).

09 · Balance Sheet

Annual

Line itemFY23FY24FY25FY26
₹1,592.82 Cr₹1,912.10 Cr₹2,139.22 Cr₹2,813.15 Cr
₹575.68 Cr₹686.71 Cr₹682.07 Cr₹364.19 Cr
Stockholders' equity
₹686.56 Cr₹882.80 Cr₹1,052.09 Cr₹2,021.98 Cr

CWIP, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY23FY24FY25FY26
₹195.03 Cr₹361.44 Cr₹215.38 Cr₹329.09 Cr
Investing cash flow
₹-179.63 Cr₹-254.55 Cr₹-100.15 Cr₹-333.45 Cr
₹1.51 Cr₹-130.30 Cr₹-88.86 Cr₹120.84 Cr
Capital expenditure
₹-98.43 Cr₹-71.45 Cr₹-145.12 Cr₹-119.69 Cr
End cash position
₹100.05 Cr₹76.63 Cr₹103.00 Cr₹236.85 Cr

Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemDec 25–Jun 26(4Q)
Promoter82.89%
Public17.11%
Employee trusts0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Park Medi World Limited₹9,659.70 Cr₹230.4534.04.7812.8%0.18+18.6%—

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

2 indices

PARKHOSPS

Park Medi World Posts Record FY26 Revenue and Profit; Targets 5,740-Bed Network by March 2028

Park Medi World Limited posted its strongest FY26 results, with revenue up 21% to ₹1,679.4 crore and profit after tax rising 27% to ₹273.6 crore, driven by higher occupancy, increased ARPOB and disciplined cost management. The company now aims to expand its bed network to 5,740 by March 2028 through acquisitions, greenfield projects and operating‑and‑managing arrangements across six states.

PARKHOSPS

Park Medi World Shares Tumble As Q2 Profit Falls 30%, Margins Contract On Expansion Costs

BW Businessworld · 6 days ago